October 2023 - Page 3 of 4 - BioMedWire (BMW)

MondayOct 16, 2023 2:46 pm

Everything You Need to Know About Nonreactive Hep B Screening Results

An estimated 1.2 million people in the United States. and 350 million globally are infected with hepatitis B, a type of viral infection that attacks the liver. The condition is often characterized by symptoms such as dark urine, fever, appetite loss, abdominal pain, fatigue and weakness, jaundice and joint pain. Around 1% of hepatitis patients will develop fulminant hepatitis, a dangerous condition that can lead to liver failure and death while 5% of patients who develop hepatitis B in adulthood will develop chronic hepatitis B. However, the majority of hepatitis B patients can manage the condition through pharmaceuticals, eating a…

MondayOct 16, 2023 12:00 pm

PaxMedica Inc. (NASDAQ: PXMD) Announces Gold Sponsorship for The BRAIN Foundation’s Synchrony Symposia 2023

The BRAIN Foundation's Synchrony Symposia is the first and only international symposium on translational research for Autism Spectrum Disorder (“ASD”) PaxMedica Chairman and CEO Howard Weisman says that participating at the symposium is pivotal in advancing and fostering autism research As a Gold Sponsor, PaxMedica will have purview to the symposium’s interdisciplinary discussions, insights, and research presentations, clinical roundtables, mentor-mentee sessions, and more PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, recently announced its Gold Sponsorship…

MondayOct 16, 2023 11:15 am

Clene Inc. (NASDAQ: CLNN) Applies Patented Nanotechnology to Development of CNM-Au8(R), its Investigational Drug for ALS

In line with recent emphasis on the growing importance of nanotechnology in the US, Clene Nanomedicine innovated its investigational drug, CNM-Au8(R), using nanotechnology for the treatment of neurodegenerative disease Clene’s nanotechnological approach was recently recognized by the NINDS of NIH with a substantial grant to conduct an Expanded Access Protocol in ALS with CNM-Au8(R) Clene aims to file a New Drug Application for CNM-Au8(R) for ALS indications in the first half of 2024 October 2023 has turned into a month for the celebration of nanotechnology. On Wednesday, Oct. 4, 2023, three U.S.-based scientists, Moungi Bawendi, Louis Brus, and Aleksey Ekimov,…

FridayOct 13, 2023 12:38 pm

A Deeper Look at the $9.99 Pricing Strategy in eCommerce

Anyone who has browsed through online or physical stores has noticed that retailers have a propensity for slapping price tags that end with .99 on their products. This method has been a common practice in commerce for decades, and according to consumer behavior experts, ending product prices with .99 helps to sell more goods as consumers tend to resonate with the first digit of a price. Consequently, consumers are more likely to purchase a product worth $9.99 over a $10.00 product even though both products essentially cost the same. With e-commerce constantly growing and evolving as millions of retailers fight…

ThursdayOct 12, 2023 1:46 pm

Researchers Look for Novel Immunomodulating Targets with Potential to Transform Glioblastoma Treatment

Glioblastoma remains one of the most debilitating and difficult-to-treat types of brain cancer. This type of cancer originates from the supportive tissue of nerve cells in the brain and spinal cord before very quickly invading and damaging healthy brain tissue. The speed with which glioblastomas proliferate, their proximity to crucial brain tissue and their potent immune-suppression abilities make treating glioblastomas incredibly difficult and often result in low survival outcomes for patients once they are diagnosed. With a five-year survival rate of only 6.9% and an average postdiagnosis survival rate of around eight months, glioblastoma takes more than 100,000 lives in…

ThursdayOct 12, 2023 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) CEO Presents ASD Pipeline and Corporate Presentation at H.C. Wainwright 25th Annual Global Investment Conference

Howard Weisman presented PaxMedica’s goals and plans to investors at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 The presentation defined the company’s intention to generate significant funding for its ASD program by first gaining approval for suramin sodium in the treatment of a rare and deadly infection using the same drug The global ASD treatment market was valued at $2.02 billion and is expected to reach $3.28 billion by 2030 Howard Weisman, CEO of PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum…

WednesdayOct 11, 2023 2:37 pm

Syndromic Testing Could Transform Infectious Disease Diagnosis

The coronavirus pandemic put a spotlight on the potential danger of infectious diseases and has helped spur research to develop faster and more efficient means of diagnosing infectious diseases. Early diagnosis of infectious diseases is critical to developing proper treatment and prevention protocols. It can save a patient’s life and prevent them from spreading the infectious disease to other people while they are still undiagnosed, reducing the likelihood of outbreaks occurring and crippling healthcare systems. With the demand for quick and accurate infectious disease diagnosis rising by the day, researchers are constantly working to develop novel techniques such as syndromic…

TuesdayOct 10, 2023 3:27 pm

Patients with Metastatic Solid Tumors Have Better Outcomes After Prophylactic Radiation, Study Finds

A new study has revealed that prophylactic radiation may be able to improve treatment outcomes for patients with solid metastatic tumors. Prophylactic cranial radiation (PCR) or prophylactic cranial irradiation (PCI) is a type of radiation therapy used to kill cancer cells from cancers such as small-cell lung cancer that have spread to the brain and prevent further invasion of brain tissue. According to a paper published in the “Journal of Clinical Oncology,” applying prophylactic radiation to asymptomatic bone metastases in patients diagnosed with solid tumor malignancies can improve patient outcomes. During phase 2 trials, patients who received prophylactic radiation reported…

MondayOct 09, 2023 10:28 am

Five Must-Have Design Features for e-Commerce Sites

With a share of close to 19% of total retail sales, e-commerce plays an increasingly large role in the American retail market. Millions of online stores are fighting to attract customers, and around 80% to 90% of them fail before they can build a market presence. Although this extremely high failure rate is caused by factors such as poor marketing, limited search visibility and intense competition, poor design can also lower your website’s chances of success. To stand out from the more than 26.5 million e-commerce websites fighting to succeed in the online sales segment, you will have to implement…

FridayOct 06, 2023 11:52 am

First Time Ever: Researchers Eliminate Brain Cancer Using Quantum Therapy

University of Nottingham scientists have developed a new quantum therapeutic approach to treating cancer that could treat one of the most aggressive types of brain cancer, glioblastoma. The researchers created a new spray treatment capable of treating glioblastoma through quantum signaling, making their treatment the first-ever, quantum-therapy-based treatment. This unique treatment works by changing neural cells at a quantum level via bio-nanoantennas, nano-particles of gold coated in redox-active molecules. According to the researchers, the novel treatment involves spraying glioblastoma tumor sites with bio-nanoantennae followed by the application of an electric field. University of Nottingham research fellow and study coauthor Frannkie…